Subtype of EGFR exon 19 deletion mutations.
作者信息
Fujimoto Nobukazu
机构信息
Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan.
出版信息
Transl Lung Cancer Res. 2024 Jan 31;13(1):195-198. doi: 10.21037/tlcr-23-680. Epub 2024 Jan 17.
Abstract
摘要
相似文献
1
Subtype of EGFR exon 19 deletion mutations.表皮生长因子受体（EGFR）第19外显子缺失突变的亚型
Transl Lung Cancer Res. 2024 Jan 31;13(1):195-198. doi: 10.21037/tlcr-23-680. Epub 2024 Jan 17.
2
A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.一项关于携带罕见表皮生长因子受体（EGFR）突变的非小细胞肺癌的多中心回顾性研究：EGFR外显子19缺失插入的不同亚型表现出非小细胞肺癌的临床特征和预后。
Transl Lung Cancer Res. 2022 Feb;11(2):238-249. doi: 10.21037/tlcr-22-48.
3
Genomic profiling reveals non-small cell lung cancer with common mutations of exon 20 and exon 21: a case report.基因组分析揭示具有外显子20和外显子21常见突变的非小细胞肺癌：一例报告
Transl Cancer Res. 2022 May;11(5):1423-1428. doi: 10.21037/tcr-21-2604.
4
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.不同寻常的表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）在罕见 EGFR 突变患者中的反应：在这一复杂临床情况下的新见解和未来展望。
Int J Mol Sci. 2019 Mar 21;20(6):1431. doi: 10.3390/ijms20061431.
5
exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review.外显子19缺失转换及p.L792Q突变的发生作为奥希替尼新的耐药机制：一例报告及文献综述
Transl Cancer Res. 2019 Jan;8(Suppl 1):S64-S69. doi: 10.21037/tcr.2018.09.13.
6
Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.对携带表皮生长因子激活突变的非小细胞肺癌患者中酪氨酸激酶抑制剂耐药性肿瘤进行下一代测序。
BMC Cancer. 2015 Nov 16;15:908. doi: 10.1186/s12885-015-1925-2.
7
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.携带罕见 EGFR 外显子 19 缺失-插入突变的患者对第一代 EGFR 抑制剂和奥希替尼治疗敏感，奥希替尼是在获得 T790M 后使用的。
BMC Cancer. 2021 Nov 13;21(1):1215. doi: 10.1186/s12885-021-08942-x.
8
Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.免疫检查点抑制剂治疗携带表皮生长因子受体突变的非小细胞肺癌患者的临床结局。
BMC Pulm Med. 2023 May 5;23(1):158. doi: 10.1186/s12890-023-02466-9.
9
Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.非小细胞肺癌患者中罕见的表皮生长因子受体基因突变、酪氨酸激酶抑制剂反应和预后分析。
Cancer Treat Res Commun. 2021;28:100398. doi: 10.1016/j.ctarc.2021.100398. Epub 2021 May 13.
10
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.比较携带表皮生长因子受体外显子 19 或外显子 21 突变的非小细胞肺癌患者的临床结局。
J Clin Pathol. 2011 Nov;64(11):947-52. doi: 10.1136/jclinpath-2011-200169. Epub 2011 Jul 1.
引用本文的文献
1
A handheld microfluidic manifold for massively multiplexed CRISPR-based nucleic acid detection.一种用于基于CRISPR的大规模多重核酸检测的手持式微流控歧管。
bioRxiv. 2025 Aug 12:2025.08.11.669785. doi: 10.1101/2025.08.11.669785.
本文引用的文献
1
A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.一项阿法替尼单药或联合贝伐珠单抗治疗未经化疗的 EGFR 突变型非小细胞肺癌患者的随机 II 期研究。
Lung Cancer. 2023 Oct;184:107349. doi: 10.1016/j.lungcan.2023.107349. Epub 2023 Aug 19.
2
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.奥希替尼治疗罕见 EGFR 外显子 19 缺失突变阳性肺癌患者的疗效。
Clin Cancer Res. 2023 Jun 1;29(11):2123-2130. doi: 10.1158/1078-0432.CCR-22-3497.
3
Osimertinib in NSCLC With Atypical -Activating Mutations: A Retrospective Multicenter Study.奥希替尼治疗非小细胞肺癌伴有非典型激活突变：一项回顾性多中心研究。
JTO Clin Res Rep. 2023 Jan 10;4(3):100459. doi: 10.1016/j.jtocrr.2022.100459. eCollection 2023 Mar.
4
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.奥希替尼联合贝伐珠单抗对比奥希替尼一线治疗携带 EGFR 突变的非鳞状非小细胞肺癌的随机 II 期研究：WJOG9717L 研究。
J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27.
5
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.阿法替尼治疗具有罕见表皮生长因子受体（EGFR）突变的非小细胞肺癌：一个包含693例病例的数据库。
J Thorac Oncol. 2020 May;15(5):803-815. doi: 10.1016/j.jtho.2019.12.126. Epub 2020 Jan 10.
6
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).奥希替尼治疗携带非典型 EGFR 突变的非小细胞肺癌患者：一项多中心、开放标签、II 期试验（KCSG-LU15-09）。
J Clin Oncol. 2020 Feb 10;38(5):488-495. doi: 10.1200/JCO.19.00931. Epub 2019 Dec 11.
7
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
8
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.吉非替尼单药对比吉非替尼联合化疗用于表皮生长因子受体突变的非小细胞肺癌：NEJ009 研究。
J Clin Oncol. 2020 Jan 10;38(2):115-123. doi: 10.1200/JCO.19.01488. Epub 2019 Nov 4.
9
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.雷莫芦单抗联合厄洛替尼治疗未经治疗的表皮生长因子受体突变型、晚期非小细胞肺癌患者（RELAY）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.
10
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in -Mutated Lung Cancer.吉非替尼对比吉非替尼联合培美曲塞和顺铂化疗用于 - 突变型肺癌。
J Clin Oncol. 2020 Jan 10;38(2):124-136. doi: 10.1200/JCO.19.01154. Epub 2019 Aug 14.
Zotero 插件